It has been well documented that binding of anti-CD38 mAb Daratumumab, anti-CD20 mAb rituximab, anti-HER2 mAb trastuzumab, anti-EGFR mAb cetuximab etc. to cancer cells promotes trogocytosis mediated by monocytes and other FcγR+ cells (25, 35, 36). This evidence concerns the gene CD38 and cancer.